Telix Pharma Mediaroom - PR Newswire APAC

Telix H1 2026 Results: Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-07-31 06:41 603

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-07-21 06:52 4588

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

• First patient dosed in Phase 3 LUTEON[1] trial evaluating TLX250-Tx in relapsed or recurrent cle...

2026-07-21 05:00 2680

Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study

* Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for...

2026-07-17 06:00 4192

Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing

* First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured ...

2026-07-16 08:30 4390

First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer

* First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-...

2026-07-16 04:30 3495

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-06-23 05:37 6010

IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing

* IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment. * Maximum dose rea...

2026-05-19 05:00 7344

New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC

MELBOURNE, Australia and INDIANAPOLIS, Ind., May 5, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limi...

2026-05-05 05:00 5279

TLX101-Px (Pixlumi®) MAA Accepted in Europe

MELBOURNE, Australia and INDIANAPOLIS, May 1, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (A...

2026-05-01 08:48 8339

OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

* TLX597-Tx is a PSMA[1]-targeting small molecule radioligand therapy (RLT) candidate, designed t...

2026-04-30 05:00 6333

Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach

MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2026-04-28 07:44 5926

Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma

MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2026-04-15 06:50 6182

Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds

MELBOURNE, Australia and Indianapolis, April 15, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2026-04-15 06:35 7283

Telix Refinances Convertible Bonds

MELBOURNE, Australia and INDIANAPOLIS, Ind., April 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals L...

2026-04-14 16:32 6704

Telix and Regeneron Announce Strategic Radiopharma Collaboration

* Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical ther...

2026-04-13 06:57 5883

FDA Accepts NDA for TLX101-Px (Pixclara®)

MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2026-04-10 06:50 6663

Telix Strengthens Board with Additional Director Appointments

MELBOURNE, Australia and INDIANAPOLIS, April 8, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2026-04-09 06:58 5043

Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-04-07 06:57 7031

Telix Appoints David Gill as Non-Executive Director

MELBOURNE, Australia and INDIANAPOLIS, April 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-04-02 06:59 5643

Latest News